Movement Alert｜Abivax S.A. Falls 5.62% in Regular Trading, Phase 3 Trial Safety Concerns Continue to Suppress Rebound Momentum

Market Focus06-26

On June 26, Abivax S.A. declined 5.62% in regular trading, trading at approximately $87.54/share, with turnover of $94.35 million.

On the news front, the company's core drug candidate obefazimod faced persistent safety concerns stemming from its Phase 3 ABTECT maintenance trial, where multiple cancer cases emerged in the 50mg dosage group. The stock had previously plunged from around $130 to approximately $70 — a decline of nearly 50%. Some investors subsequently argued the cancer cases were more likely age-related and that the initial selloff was excessive, driving a partial rebound above $100. However, the market remains divided on the safety implications, and as technical rebound momentum continues to weaken, the stock has resumed its downward trajectory.

Within the Biotechnology sector, among notable peers, AbbVie rose 3.09%, Revolution Medicines rose 4.94%, Ascendis Pharma rose 9.0%, Apogee Therapeutics rose 0.01%, while Gilead Sciences fell 0.42%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188776658?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 00:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188776658","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Abivax S.A. Falls 5.62% in Regular Trading, Phase 3 Trial Safety Concerns Continue to Suppress Rebound Momentum","media":"Market Focus","content":"<p><p>On June 26, Abivax S.A. declined 5.62% in regular trading, trading at approximately $87.54/share, with turnover of $94.35 million.</p><p>On the news front, the company's core drug candidate obefazimod faced persistent safety concerns stemming from its Phase 3 ABTECT maintenance trial, where multiple cancer cases emerged in the 50mg dosage group. The stock had previously plunged from around $130 to approximately $70 — a decline of nearly 50%. Some investors subsequently argued the cancer cases were more likely age-related and that the initial selloff was excessive, driving a partial rebound above $100. However, the market remains divided on the safety implications, and as technical rebound momentum continues to weaken, the stock has resumed its downward trajectory.</p><p>Within the Biotechnology sector, among notable peers, AbbVie rose 3.09%, Revolution Medicines rose 4.94%, Ascendis Pharma rose 9.0%, Apogee Therapeutics rose 0.01%, while Gilead Sciences fell 0.42%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Abivax S.A. Falls 5.62% in Regular Trading, Phase 3 Trial Safety Concerns Continue to Suppress Rebound Momentum</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Abivax S.A. Falls 5.62% in Regular Trading, Phase 3 Trial Safety Concerns Continue to Suppress Rebound Momentum\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 00:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Abivax S.A. declined 5.62% in regular trading, trading at approximately $87.54/share, with turnover of $94.35 million.</p><p>On the news front, the company's core drug candidate obefazimod faced persistent safety concerns stemming from its Phase 3 ABTECT maintenance trial, where multiple cancer cases emerged in the 50mg dosage group. The stock had previously plunged from around $130 to approximately $70 — a decline of nearly 50%. Some investors subsequently argued the cancer cases were more likely age-related and that the initial selloff was excessive, driving a partial rebound above $100. However, the market remains divided on the safety implications, and as technical rebound momentum continues to weaken, the stock has resumed its downward trajectory.</p><p>Within the Biotechnology sector, among notable peers, AbbVie rose 3.09%, Revolution Medicines rose 4.94%, Ascendis Pharma rose 9.0%, Apogee Therapeutics rose 0.01%, while Gilead Sciences fell 0.42%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1188776658","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188776658","pubTimestamp":1782405250,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Abivax S.A. declined 5.62% in regular trading, trading at approximately $87.54/share, with turnover of $94.35 million.On the news front, the company's core drug candidate obefazimod faced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"动向提示|Abivax S.A.常规交易跌5.62%，3期试验安全性担忧继续打压反弹动能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"On June 26, Abivax S.A. declined 5.62% in regular trading, trading at approximately $87.54/share, with turnover of $94.35 million.On the news front, the company's core drug candidate obefazimod faced persistent safety concerns stemming from its Phase 3 ABTECT maintenance trial, where multiple cancer cases emerged in the 50mg dosage group. The stock had previously plunged from around $130 to approximately $70 — a decline of nearly 50%. Some investors subsequently argued the cancer cases were more likely age-related and that the initial selloff was excessive, driving a partial rebound above $100. However, the market remains divided on the safety implications, and as technical rebound momentum continues to weaken, the stock has resumed its downward trajectory.Within the Biotechnology sector, among notable peers, AbbVie rose 3.09%, Revolution Medicines rose 4.94%, Ascendis Pharma rose 9.0%, Apogee Therapeutics rose 0.01%, while Gilead Sciences fell 0.42%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188776658","isCrawlerRequest":true}